Genetic variants in PI3K/AKT pathway are associated with severe radiation pneumonitis in lung cancer patients treated with radiation therapy

被引:33
作者
Tang, Yang [1 ]
Liu, Bo [1 ]
Li, Jing [1 ]
Wu, Huanlei [1 ]
Yang, Ju [1 ]
Zhou, Xiao [1 ]
Yi, Mingxiao [1 ]
Li, Qianxia [1 ]
Yu, Shiying [1 ]
Yuan, Xianglin [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Wuhan 430074, Hubei Province, Peoples R China
来源
CANCER MEDICINE | 2016年 / 5卷 / 01期
基金
中国国家自然科学基金;
关键词
AKT; lung cancer; PI3CA; PI3K; radiation pneumonitis; SNP; FIBROSIS; RISK; INHIBITION; TGF-BETA-1; TOXICITY;
D O I
10.1002/cam4.564
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PI3K/AKT pathway plays important roles in inflammatory and fibrotic diseases while its connection to radiation pneumonitis (RP) is unclear. In this study, we explored the associations of genetic variants in PI3K/AKT pathway with RP in lung cancer patients with radiotherapy. Two hundred and sixty one lung cancer patients with radiotherapy were included in this prospective study (NCT02490319) and genotyped by MassArray and Sanger Sequence methods. By multivariate Cox hazard analysis and multiple testing, GA/GG genotype of AKT2: rs33933140 (HR=0.272, 95% CI: 0.140-0.530, P=1.3E-4, P-c=9.1E-4), and the GT/GG genotype of PI3CA: rs9838117 (HR=0.132, 95% CI: 0.042-0.416, P=0.001, P-c=0.006) were found to be strongly associated with a decreased occurrence of RPgrade 3. And patients with the CT/TT genotype of AKT2: rs11880261 had a notably higher incidence of RPgrade 3 (HR=2.950, 95% CI: 1.380-6.305, P=0.005, P-c=0.025). We concluded that the genetic variants of PI3K/AKT pathway were significantly related to RP of grade3 and may thus be predictors of severe RP before radiotherapy, if further validated in larger population.
引用
收藏
页码:24 / 32
页数:9
相关论文
共 33 条
[1]   Genetic variants and normal tissue toxicity after radiotherapy: A systematic review [J].
Andreassen, Christian Nicolaj ;
Alsner, Jan .
RADIOTHERAPY AND ONCOLOGY, 2009, 92 (03) :299-309
[2]  
[Anonymous], 2013, LANCET, V382, P659, DOI 10.1016/S0140-6736(13)61759-6
[3]  
[Anonymous], BIOCH BIOPHYS ACTA M
[4]   PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer [J].
Barber, Alison G. ;
Castillo-Martin, Mireia ;
Bonal, Dennis M. ;
Jia, Angela J. ;
Rybicki, Benjamin A. ;
Christiano, Angela M. ;
Cordon-Cardo, Carlos .
CANCER MEDICINE, 2015, 4 (08) :1258-1271
[5]   FOXO transcription factors as regulators of immune homeostasis: Molecules to die for? [J].
Birkenkamp, KU ;
Coffer, PJ .
JOURNAL OF IMMUNOLOGY, 2003, 171 (04) :1623-1629
[6]   PI3K p110γ overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition [J].
Conte, Enrico ;
Gili, Elisa ;
Fruciano, Mary ;
Korfei, Martina ;
Fagone, Evelina ;
Iemmolo, Maria ;
Lo Furno, Debora ;
Giuffrida, Rosario ;
Crimi, Nunzio ;
Guenther, Andreas ;
Vancheri, Carlo .
LABORATORY INVESTIGATION, 2013, 93 (05) :566-576
[7]   Inhibition of PI3K Prevents the Proliferation and Differentiation of Human Lung Fibroblasts into Myofibroblasts: The Role of Class I P110 Isoforms [J].
Conte, Enrico ;
Fruciano, Mary ;
Fagone, Evelina ;
Gili, Elisa ;
Caraci, Filippo ;
Iemmolo, Maria ;
Crimi, Nunzio ;
Vancheri, Carlo .
PLOS ONE, 2011, 6 (10)
[8]   Inhibition of PI3K Signaling Spurs New Therapeutic Opportunities in Inflammatory/Autoimmune Diseases and Hematological Malignancies [J].
Foster, John G. ;
Blunt, Matthew D. ;
Carter, Edward ;
Ward, Stephen G. .
PHARMACOLOGICAL REVIEWS, 2012, 64 (04) :1027-1054
[9]   PI3K and cancer: lessons, challenges and opportunities [J].
Fruman, David A. ;
Rommel, Christian .
NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (02) :140-156
[10]   PI3K inhibition in inflammation: Toward tailored therapies for specific diseases [J].
Ghigo, Alessandra ;
Damilano, Federico ;
Braccini, Laura ;
Hirsch, Emilio .
BIOESSAYS, 2010, 32 (03) :185-196